Skip to main content
SpringerLink
Log in

Future Developments in Adjuvant and Palliative Systemic Endocrine Therapies

  • Conference paper
Ein Jahrhundert endokrine Therapie des Mammakarzinoms

  • 20 Accesses

Abstract

The World Overview of adjuvant trials for early breast cancer published in the Lancet in January 1992 (Early Breast Cancer Trialists’ Collaborative Group 1992) provided us with secure data to allow the rational employment of adjuvant systemic chemotherapy and endocrine therapy. The World Overview also set the agenda for the next decade of clinical trials in the management of early breast cancer. A whole raft of new questions has been defined concerning the role of endocrine manipulation in both pre- and post-menopausal women.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Badwe RA, Gregory WM, Cahudary MA et al (1994) Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1: 1261–1264

    Google Scholar 

  • Benson JR, Wakefield LM, Sporn MB et al (1993) Secretion of TGFß isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen (Abstr). Breast Cancer Res Treat 27: (1/2): 163

    Google Scholar 

  • Butta A, Maclennan K, Flanders KC, Sacks NPM, Smith I, Mackinna A, Dow-sett M, Wakefield LM, Sporn MB, Colletta AA (1992) Induction of transforming growth factor beta1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261–4264

    PubMed  CAS  Google Scholar 

  • Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC (1991) Pyrrolidino-4-iodotamoxifen and 4-Iodotamoxifen. New analogues of the antiestrogen Tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851–5955

    PubMed  CAS  Google Scholar 

  • Colletta AA, Benson JR, Baum M (1994) Alternate mechanisms of action of antioestrogens. Breast Cancer Res Treatment 31: 5–9

    Article  CAS  Google Scholar 

  • Cullen KJ, Lippmann ME, Chow D, Hill S, Rosen N, Zwiebel JA (1992) Insulinlike growth factor-II over-expression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol (Oxf) 6: 91–100

    Article  CAS  Google Scholar 

  • DeFriend D, Blarney RE, Robertson JF, Walton P, Howell A (1993) Response to the pure anti-oestrogen ICI 182,780 after Tamoxifen failure in advanced breast cancer (Abst). Breast Cancer Res Treat 27 (1/2): 136

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: (8784): 1–15;

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339 (8785): 71–85

    Google Scholar 

  • Fentiman IS, Gregory WM (1994) Peri-operative hormones and prognosis in breast cancer. Eur J Cancer 30A (12): 1892–1894

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Gunduz N, Coyle J (1989) Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res 49:1996–2001

    PubMed  CAS  Google Scholar 

  • Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1; 1: pp 27, 1995

    Article  CAS  Google Scholar 

  • Folkman J: Tumor angiogenesis. In: Mendelsohn J, Howley P, Liotta L, Israel M, eds. The Molecular Basis of Cancer, W B Saunders Company, Philadelphia, in press (1994)

    Google Scholar 

  • Folkman J: What is the evidence that tumours are angiogenesis dependent? JNCI 82: 4–6, 1990

    PubMed  CAS  Google Scholar 

  • Folkman J: What is the evidence that tumours are angiogenesis dependent? JNCI 82: 4–6, 1990.

    PubMed  CAS  Google Scholar 

  • Gagliardi A, Collins DC (1993) Inhibition of angiogenesis by anti-oestrogens. Cancer Res 53: 533–535

    PubMed  CAS  Google Scholar 

  • Horak E, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. The Lancet 340: 1120–1124, 1992

    Article  CAS  Google Scholar 

  • Hori A, Sasada R, Matsutani E et al: Suppression of solid tumour growth by immuno-neutralising monoclonal antibody against fibroblasts growth factor. Cancer Res 51: 6180–6184, 1991

    PubMed  CAS  Google Scholar 

  • Huynh HT, Tetenes E, Wallace L, Pollack M (1993) In vivo inhibition of Insulinlike growth factor I gene expression by tamoxifen. Cancer Res 53:1727–1730

    PubMed  CAS  Google Scholar 

  • Jordan VC (ed) (1994) Long-term Tamoxifen therapy for breast cancer. University of Wisconsin Press, Madison

    Google Scholar 

  • Jordan VC, Morrow M (1994) Should clinicians be concerned about the carcinogenic potential of Tamoxifen? Eur J Cancer 30 (11): 1714–1721

    Article  Google Scholar 

  • Lippman ME. New Approaches in Diagnosing and Treating Breast Cancer Conference organised by Cambridge Healthtech Institute. Philadelphia November 1994

    Google Scholar 

  • Myall Y, Shiu RPC, Bhaumick, B, (1984) Receptor binding and growth promoting activity of insulin-like growth factors in human breast cancer cells (T47D) in culture. Cancer Res 44: 5486–5490

    Google Scholar 

  • Nicholson RI, Walker KJ, Turkes A et al (1985) Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem 23: 843–847

    Article  PubMed  CAS  Google Scholar 

  • Nolvadex Adjuvant Trial Organisation (1987) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 54: 608–611

    Google Scholar 

  • Shultz GS and Grant MB: Neovascular growth factors. Eye (London) 5: 178–180, 1991

    Google Scholar 

  • Steinberg KK, Thacker SB et al (1991) Meta-analysis of the effect of oestrogen replacement therapy on risk of breast cancer. JAMA 265: 1985–1990

    Article  PubMed  CAS  Google Scholar 

  • Tabar L, Fagerberg G, Hsiu-Hsi Chen et al (1995) Efficacy of breast cancer screening by age. New results from the Swedish two-country trial. Cancer 75 (10): 2507–2517

    Article  PubMed  CAS  Google Scholar 

  • Tripathy D (1994) How long should adjuvant Tamoxifen be continued? Oncology 8 (10): 25–30

    PubMed  CAS  Google Scholar 

  • Wakeling AE, Dukes M. Bowler J (1991) A potent specific pure anti-oestrogen with clinical potential. Cancer Res 51: 3867–3873

    PubMed  CAS  Google Scholar 

  • Weidner N, Semple JP, Welch WR and Folkman J: Tumour angiogenesis and metastasis — correlation in invasive breast carcinoma. NEJM 324: 1–8 1991

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum der Frauenheilkunde und Geburtshilfe, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, D-60596, Frankfurt, Deutschland

    Manfred Kaufmann

  2. Universität Hamburg Universitäts-Frauenklinik, Martinistraße 52, D-20246, Hamburg, Deutschland

    Heinrich Maass

  3. Geschäftseinheit Onkologie/Endokrinologie, Zeneca GmbH, Otto-Hahn-Straße, D-68723, Plankstadt, Deutschland

    Dieter Alt

  4. Medizinisches Referat Onkologie/Endokrinologie, Zeneca GmbH, Otto-Hahn-Straße, D-68723, Plankstadt, Deutschland

    Carl-Rudolf Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Baum, M. (1996). Future Developments in Adjuvant and Palliative Systemic Endocrine Therapies. In: Kaufmann, M., Maass, H., Alt, D., Schmidt, CR. (eds) Ein Jahrhundert endokrine Therapie des Mammakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80235-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80235-5_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61166-0

  • Online ISBN: 978-3-642-80235-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation